AUTHOR=Su Qiang , Ren Yu-Hua , Liu Guo-Wei , Gao Yan-Ping , Zhang Jiu-Xuan , Zhang Jin-Nan , Pei Xia-Xia , Li Tian 

TITLE=Trichostatin A relieves anxiety-and depression-like symptoms in APP/PS1 mice

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1333235

DOI=10.3389/fphar.2024.1333235

ISSN=1663-9812

ABSTRACT=<sec><title>Background:</title><p>Cognitive deficits and behavioral disorders such as anxiety and depression are common manifestations of Alzheimer’s disease (AD). Our previous work demonstrated that Trichostatin A (TSA) could alleviate neuroinflammatory plaques and improve cognitive disorders. AD, anxiety, and depression are all associated with microglial inflammation. However, whether TSA could attenuate anxiety- and depression-like behaviors in APP/PS1 mice through anti-inflammatory signaling is still unclearly.</p></sec><sec><title>Methods:</title><p>In the present study, all mice were subjected to the open field, elevated plus maze, and forced swim tests to assess anxiety- and depression-related behaviors after TSA administration. To understand the possible mechanisms underlying the behavioral effects observed, <italic>CST7</italic> was measured in the hippocampus of mice and LPS-treated BV2 microglia.</p></sec><sec><title>Results:</title><p>The results of this study indicated that TSA administration relieved the behaviors of depression and anxiety in APP/PS1 mice, and decreased <italic>CST7</italic> levels in the hippocampus of APP/PS1 mice and LPS-induced BV2 cells.</p></sec><sec><title>Conclusion:</title><p>Overall, these findings support the idea that TSA might be beneficial for reducing neurobehavioral disorders in AD and this could be due to suppression of <italic>CST7</italic>-related microglial inflammation.</p></sec>